174 related articles for article (PubMed ID: 13678477)
1. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.
Collantes-Estevez E; Fernandez-Perez C
Curr Med Res Opin; 2003; 19(5):402-10. PubMed ID: 13678477
[TBL] [Abstract][Full Text] [Related]
2. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
Gibofsky A; Williams GW; McKenna F; Fort JG
Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
Rahme E; Hunsche E; Toubouti Y; Chabot I
Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
[TBL] [Abstract][Full Text] [Related]
4. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
Schnitzer TJ; Kong SX; Mitchell JH; Mavros P; Watson DJ; Pellissier JM; Straus WL
Clin Ther; 2003 Dec; 25(12):3162-72. PubMed ID: 14749154
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
[TBL] [Abstract][Full Text] [Related]
6. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
[TBL] [Abstract][Full Text] [Related]
7. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Hsiao FY; Tsai YW; Huang WF
Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
Geba GP; Weaver AL; Polis AB; Dixon ME; Schnitzer TJ;
JAMA; 2002 Jan; 287(1):64-71. PubMed ID: 11754710
[TBL] [Abstract][Full Text] [Related]
9. Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study.
Arboleya LR; de la Figuera E; Soledad García M; Aragón B;
Curr Med Res Opin; 2003; 19(4):288-97. PubMed ID: 12841921
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
Birbara C; Ruoff G; Sheldon E; Valenzuela C; Rodgers A; Petruschke RA; Chang DJ; Tershakovec AM
Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
[TBL] [Abstract][Full Text] [Related]
11. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (experience with VIOXX in arthritis) survey.
Steinfeld S; Poriau S
Curr Med Res Opin; 2001; 17(2):81-7. PubMed ID: 11759186
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
[TBL] [Abstract][Full Text] [Related]
13. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
Zhao SZ; Wentworth C; Burke TA; Makuch RW
Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
[TBL] [Abstract][Full Text] [Related]
14. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
Becker RV; Burke TA; McCoy MA; Trotter JP
Clin Ther; 2003 Feb; 25(2):647-62. PubMed ID: 12749519
[TBL] [Abstract][Full Text] [Related]
15. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
Smugar SS; Schnitzer TJ; Weaver AL; Rubin BR; Polis AB; Tershakovec AM
Curr Med Res Opin; 2006 Jul; 22(7):1353-67. PubMed ID: 16834834
[TBL] [Abstract][Full Text] [Related]
16. Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis.
Ehrich EW; Bolognese JA; Watson DJ; Kong SX
Am J Manag Care; 2001 Jun; 7(6):609-16. PubMed ID: 11439734
[TBL] [Abstract][Full Text] [Related]
17. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a post-marketing surveillance study in primary care in Germany.
Zacher J; Schattenkirchner M
Curr Med Res Opin; 2002; 18(4):229-36. PubMed ID: 12201624
[TBL] [Abstract][Full Text] [Related]
18. Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension.
Osterhaus JT; Burke TA; May C; Wentworth C; Whelton A; Bristol S
Clin Ther; 2002 Jun; 24(6):969-89. PubMed ID: 12117086
[TBL] [Abstract][Full Text] [Related]
19. A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee.
Bianchi M; Broggini M
Drugs; 2003; 63 Suppl 1():37-46. PubMed ID: 14506910
[TBL] [Abstract][Full Text] [Related]
20. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
